Navigation Links
Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
Date:8/16/2010

>-1,930,000Equity:Shareholders' equity:Common stock - no par value; 100,000,000 shares authorized;20,358,586 and 20,180,486(1) shares issued and outstandingas of June 30, 2010 and December 31, 2009, respectively

68,199,16567,711,746Retained earnings

5,153,0084,542,126Total shareholders' equity

73,352,17372,253,872Noncontrolling interests

(50,143)(32,536)Total equity

73,302,03072,221,336Total liabilities and equity

$ 96,702,030$  103,724,320(1) Number of shares issued and outstanding represent total shares of common stock regardless of classification on the consolidated balance sheet. The number of shares of redeemable common stock at December 31, 2009 was 142,016.CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIESCondensed Consolidated Statements of Income(Unaudited)Three months ended June 30,Six months ended June 30,2010200920102009Net revenues

$  10,739,935$ 9,820,613$  20,870,587$  19,225,212Costs and expenses:Cost of products sold

863,725777,0761,723,0131,510,294Selling and marketing

5,848,1234,383,80211,455,6358,523,989Research and development

1,034,8002,630,7251,808,6683,400,842General and administrative

1,782,8341,236,4353,664,0372,681,298Amortization of product license right

171,726171,726343,452343,452Other

28,86726,73355,41454,196Total costs and expenses

9,730,0759,226,49719,050,21916,514,071Operating income

1,009,860594,1161,820,3682,711,141Interest income

50,33410,160111,01327,756Interest expense

(405,956)(84,224)(751,908)(181,935)Net income before income taxes

654,238520,0521,179,4732,556,962Income tax expense

(374,461)(232,637)(586,198)(1,063,696)Net income

279,777287,415593,2751,493,266Net loss at subsidiary attributable tononcontrolling interests

7,5278,45617,60720,695Net income attributable tocommon shareholders

$
287,304$
295,871$
,882$
,513,961Earnings per share attri
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
2. Cumberland Pharmaceuticals to Present at Jefferies Global Life Sciences Conference in New York on June 8, 2010
3. Cumberland Pharmaceuticals To Announce First Quarter 2010 Financial Results on May 13, 2010
4. Cumberland Pharmaceuticals Partners in Canada With Alveda Pharmaceuticals to Commercialize Caldolor(R)
5. Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
6. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
7. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
8. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
9. Ferring Pharmaceuticals FIRMAGON® Joins Race to End Prostate Cancer as Official Sponsor of the Great Prostate Cancer Challenge / Dash for Dad
10. Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets
11. Lotus Pharmaceuticals Reports Strong Second Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ) today ... June 30, 2014. Financial Results for the Six ... revenue for the quarter ended June 30, 2014 increased to ... 30, 2013 primarily due to IMBRUVICA ® (ibrutinib) net ... for the six months ended June 30, 2014 increased to ...
(Date:7/31/2014)... VIEW, Calif. , July 31, 2014 /PRNewswire/ ... today provided an update on its pipeline and ... 2014, Alexza expects to initiate a Phase 2a ... is being developed for the management of patients ... two new Staccato -based product candidates for ...
(Date:7/31/2014)... , July 31, 2014 Rock Creek Pharmaceuticals, ... it has initiated the development of its lead molecule, ... that it has selected Quotient Clinical, The Translational Pharmaceutics ... (UK) to run its early development programs. ... Application (CTA) by the end of the third quarter ...
Breaking Medicine Technology:Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4
... March 30, 2011 Neurocrine Biosciences, Inc. (Nasdaq: ... Executive Officer of Neurocrine Biosciences, will be presenting at the ... The live presentation takes place on Wednesday, ... a.m. Pacific Time.  The presentation will be webcast and may ...
... 2011 CANTEL MEDICAL CORP. (NYSE: ... President, will be presenting at the Needham & Company, LLC ... 4:00 PM EDT on Wednesday, April 6, 2011 at the ... immediately following the presentation.  In addition, Mr. Segel will be ...
Cached Medicine Technology:
(Date:8/1/2014)... benefits of a cancer diagnosis may improve health outcomes ... conducted by a researcher at the University of Houston ... writing intervention is the writing instruction. Otherwise, writing is ... a journal can be therapeutic, but oftentimes we don,t ... or not," said Qian Lu, assistant professor and director ...
(Date:8/1/2014)... 01, 2014 Hot off the presses after ... category of the World’s Best Awards by Travel + ... celebration of National Relaxation Day (technically August 15). , ... MAJOR experts to help guests celebrate relaxation throughout the month ... for health and wellness to carve out time to relax ...
(Date:8/1/2014)... Mozes HealthDay Reporter FRIDAY, ... serve as a time-honored destination for a good cut and ... might also be the spot to tackle an often overlooked ... a novel partnership, the U.S. Centers for Disease Control and ... enlisted the help of barbershop staff to both discuss and ...
(Date:8/1/2014)... August 01, 2014 For years, proponents ... A recent study conducted by the Ohio ... too far behind in terms of their health and ... know what’s best for their baby. So does this ... Dr. Steven Shapiro , chair of Pediatrics at ...
(Date:8/1/2014)... GlobalDatas new report, "United ... provides key market data on the United ... value, in millions of US dollars, volume ... dollars) within market segments - Electrosurgical RF ... Plasma Coagulation Generators. , To view the ...
Breaking Medicine News(10 mins):Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 2Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 4Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 2Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 3Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 3Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 2Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 3
... and Drug Administration (FDA) has approved the NeuRx Diaphragm ... dependent on ventilators for breathing. The light-weight, battery-powered ... naturally, while eliminating the need for a power source ... was developed over the course of 20 years through ...
... safety program launched more than two years ago ... significantly improved communication between caregivers and patients and ... the program has found. , Children,s Hospital became ... with the Josie King Foundation to launch a ...
... proVision(TM) Now Manages Over 150,000 Identities, ANDOVER, ... the past six months, seven healthcare organizations have ... processes that eliminate the challenges of manual user ... (Nashville, TN) -- Baptist Health System (Birmingham, ...
... inspiring stories of Minnesotans who ... struggled to ... personally struggled to go smoke-free are sharing their,stories, from the time ... Their inspiring stories will be showcased in,ClearWay Minnesota,s traveling photo essay ...
... born by Caesarean section have a 50 % increased risk ... sections increase the risk even further. This is shown in ... registered at the Medical Birth Registry at the Norwegian Institute ... was to investigate the possible link between being born by ...
... CHAPEL HILL Psychosocial influences such as stress, depression ... studies involving people infected with HIV, yet they are ... individuals and the spread of AIDS, according to a ... , Now, a comprehensive update on those influences in ...
Cached Medicine News:Health News:FDA approves NeuRx diaphragm pacing system for use in spinal cord- injured patients 2Health News:Study finds Children's Hospital patient safety program improves caregiver/family communications 2Health News:Leading Healthcare Organizations Overwhelmingly Select Sentillion for User Provisioning 2Health News:Leading Healthcare Organizations Overwhelmingly Select Sentillion for User Provisioning 3Health News:In Smoke-Free Minnesota, Five Former Smokers Share Their Struggles With Fighting Addiction 2Health News:In Smoke-Free Minnesota, Five Former Smokers Share Their Struggles With Fighting Addiction 3Health News:In Smoke-Free Minnesota, Five Former Smokers Share Their Struggles With Fighting Addiction 4Health News:Caesarean sections associated with risk of asthma 2Health News:Psychosocial issues affect HIV/AIDS treatment outcomes: UNC researcher 2Health News:Psychosocial issues affect HIV/AIDS treatment outcomes: UNC researcher 3
... Parathyroid hormone (PTH) is synthesized ... secreted in response to decreased extracellular ... enhancing bone resorption and decreasing calcium ... into the circulation, intact PTH is ...
... the adrenal cortex and, to a lesser ... a precursor in testosterone and estrogen synthesis, ... at ~10% that of testosterone [1]. However, ... women, DHEA is an important androgen as ...
... steroid, is one of the most potent ... testosterone is secreted primarily by the testes ... peripheral conversion of androstenedione [2]. In adult ... 50% of serum testosterone is derived from ...
... Thyroxine (T4) is the primary active ... the thyroid gland [1]. T4 is synthesized ... iodide trapping by the follicular cells, (ii) ... substrate leading to formation of 3-monoiodotyrosine and ...
Medicine Products: